1
|
Nagafusa T, Mizushima T, Suzuki M, Yamauchi K. Comprehensive relationship between disease activity indices, mTSS, and mHAQ and physical function evaluation and QOL in females with rheumatoid arthritis. Sci Rep 2023; 13:21905. [PMID: 38081947 PMCID: PMC10713608 DOI: 10.1038/s41598-023-49380-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 12/07/2023] [Indexed: 12/18/2023] Open
Abstract
Rheumatoid arthritis (RA) causes significant physical disability. We comprehensively investigated the relationship between RA disease activity (Disease Activity Score 28-C-reactive protein [DAS28-CRP], Simplified Disease Activity Index [SDAI], and Clinical Disease Activity Index [CDAI]), physical function (10-Meter Walk Test [10 MWT], Timed Up and Go test [TUG], Functional Reach Test [FRT], and Disabilities of the Arm, Shoulder, and Hand [DASH]), and quality of life (QOL) (Short-Form 36 [SF-36®]). We also investigated the relationship between van der Heijde's modified Total Sharp Score (mTSS), modified Health Assessment Questionnaire (mHAQ), and physical function and QOL assessments. Among 35 female patients with RA, DAS28-CRP correlated solely with DASH (r = 0.376), while SDAI and CDAI did not correlate with physical function. The mTSS-hand roentgenographic evaluation correlated with TUG (r = 0.359), FRT (r = - 0.415), and DASH (r = 0.533) among physical function assessments. The mHAQ correlated with 10 MWT (r = 0.347), TUG (r = 0.356), FRT (r = - 0.420), and DASH (r = 0.646). DAS28-CRP correlated with six of the eight subscales of SF-36®, and mTSS and mHAQ correlated with only one subscale. RA disease activity assessments may not reflect all physical functions and QOL domains of female patients with RA. Evaluating physical function and QOL in female patients with RA is essential.
Collapse
Affiliation(s)
- Tetsuyuki Nagafusa
- Department of Rehabilitation Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
| | - Takashi Mizushima
- Department of Rehabilitation Medicine, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, Japan
| | - Motohiro Suzuki
- Department of Orthopaedic Surgery, Omaezaki City General Hospital, Omaezaki, Shizuoka, Japan
- Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Katsuya Yamauchi
- Department of Rehabilitation Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-Ku, Hamamatsu, Shizuoka, 431-3192, Japan
| |
Collapse
|
2
|
Wang H, Ou Y, Fang W, Ambalathankandy P, Goto N, Ota G, Okino T, Fukae J, Sutherland K, Ikebe M, Kamishima T. A deep registration method for accurate quantification of joint space narrowing progression in rheumatoid arthritis. Comput Med Imaging Graph 2023; 108:102273. [PMID: 37531811 DOI: 10.1016/j.compmedimag.2023.102273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 07/15/2023] [Accepted: 07/15/2023] [Indexed: 08/04/2023]
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that leads to progressive articular destruction and severe disability. Joint space narrowing (JSN) has been regarded as an important indicator for RA progression and has received significant attention. Radiology plays a crucial role in the diagnosis and monitoring of RA through the assessment of joint space. A new framework for monitoring joint space by quantifying joint space narrowing (JSN) progression through image registration in radiographic images has emerged as a promising research direction. This framework offers the advantage of high accuracy; however, challenges still exist in reducing mismatches and improving reliability. In this work, we utilize a deep intra-subject rigid registration network to automatically quantify JSN progression in the early stages of RA. In our experiments, the mean-square error of the Euclidean distance between the moving and fixed images was 0.0031, the standard deviation was 0.0661 mm and the mismatching rate was 0.48%. Our method achieves sub-pixel level accuracy, surpassing manual measurements significantly. The proposed method is robust to noise, rotation and scaling of joints. Moreover, it provides misalignment visualization, which can assist radiologists and rheumatologists in assessing the reliability of quantification, exhibiting potential for future clinical applications. As a result, we are optimistic that our proposed method will make a significant contribution to the automatic quantification of JSN progression in RA. Code is available at https://github.com/pokeblow/Deep-Registration-QJSN-Finger.git.
Collapse
Affiliation(s)
- Haolin Wang
- Graduate School of Health Sciences, Hokkaido University, Sapporo, 060-0812, Hokkaido, Japan
| | - Yafei Ou
- Research Center For Integrated Quantum Electronics, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan; Graduate School of Information Science and Technology, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan.
| | - Wanxuan Fang
- Graduate School of Health Sciences, Hokkaido University, Sapporo, 060-0812, Hokkaido, Japan
| | - Prasoon Ambalathankandy
- Research Center For Integrated Quantum Electronics, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan; Graduate School of Information Science and Technology, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan
| | - Naoto Goto
- Research Center For Integrated Quantum Electronics, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan; Graduate School of Information Science and Technology, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan
| | - Gen Ota
- Research Center For Integrated Quantum Electronics, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan; Graduate School of Information Science and Technology, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan
| | - Taichi Okino
- Department of Radiological Technology, Sapporo City General Hospital, Sapporo, 060-8604, Hokkaido, Japan
| | - Jun Fukae
- Kuriyama Red Cross Hospital, Yubari, 069-1513, Hokkaido, Japan
| | - Kenneth Sutherland
- Global Center for Biomedical Science and Engineering, Hokkaido University, Sapporo, 060-8638, Hokkaido, Japan
| | - Masayuki Ikebe
- Research Center For Integrated Quantum Electronics, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan; Graduate School of Information Science and Technology, Hokkaido University, Sapporo, 060-0813, Hokkaido, Japan
| | - Tamotsu Kamishima
- Faculty of Health Sciences, Hokkaido University, Sapporo, 060-0812, Hokkaido, Japan
| |
Collapse
|
3
|
Parashar A, Rishi R, Parashar A, Rida I. Medical imaging in rheumatoid arthritis: A review on deep learning approach. Open Life Sci 2023; 18:20220611. [PMID: 37426615 PMCID: PMC10329279 DOI: 10.1515/biol-2022-0611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 04/04/2023] [Accepted: 04/06/2023] [Indexed: 07/11/2023] Open
Abstract
Arthritis is a musculoskeletal disorder. Millions of people have arthritis, making it one of the most common joint disorders. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common types of arthritis among the many different types available. Pain, stiffness, and inflammation are among the early signs of arthritis, which can progress to severe immobility at a later stage if left untreated. Although arthritis cannot be cured at any point in time, it can be managed if diagnosed and treated correctly. Clinical diagnostic and medical imaging methods are currently used to evaluate OA and RA, both debilitating conditions. This review is focused on deep learning approaches used by taking medical imaging (X-rays and magnetic resonance imaging) as input for the detection of RA.
Collapse
Affiliation(s)
- Apoorva Parashar
- Department of Computer Science and Engineering, Maharshi Dayanand University, Rohtak, India
| | - Rahul Rishi
- Department of Computer Science and Engineering, Maharshi Dayanand University, Rohtak, India
| | - Anubha Parashar
- Department of Computer Science and Engineering, Manipal UniversityJaipur, India
| | - Imad Rida
- BMBI Laboratory, University of Technology of Compiègne, 60200, Compiègne, France
| |
Collapse
|
4
|
Okino T, Ou Y, Ikebe M, Tamura K, Sutherland K, Fukae J, Tanimura K, Kamishima T. Fully automatic software for detecting radiographic joint space narrowing progression in rheumatoid arthritis: phantom study and comparison with visual assessment. Jpn J Radiol 2022; 41:510-520. [PMID: 36538163 DOI: 10.1007/s11604-022-01373-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Accepted: 12/06/2022] [Indexed: 12/24/2022]
Abstract
PURPOSE We have developed an in-house software equipped with partial image phase-only correlation (PIPOC) which can automatically quantify radiographic joint space narrowing (JSN) progression. The purpose of this study was to evaluate the software in phantom and clinical assessments. MATERIALS AND METHODS In the phantom assessment, the software's performance on radiographic images was compared to the joint space width (JSW) difference using a micrometer as ground truth. A phantom simulating a finger joint was scanned underwater. In the clinical assessment, 15 RA patients were included. The software measured the radiological progression of the finger joints between baseline and the 52nd week. The cases were also evaluated with the Genant-modified Sharp score (GSS), a conventional visual scoring method. We also quantitatively assessed these joints' synovial vascularity (SV) on power Doppler ultrasonography (0, 8, 20 and 52 weeks). RESULTS In the phantom assessment, the PIPOC software could detect changes in JSN with a smallest detectable difference of 0.044 mm at 0.1 mm intervals. In the clinical assessment, the JSW change of the joints with GSS progression detected by the software was significantly greater than those without GSS progression (p = 0.004). The JSW change of joints with positive SV at baseline was significantly higher than those with negative SV (p = 0.024). CONCLUSION Our in-house software equipped with PIPOC can automatically and quantitatively detect slight radiographic changes of JSW in clinically inactive RA patients.
Collapse
|
5
|
Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA. Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study. BMC Rheumatol 2022; 6:24. [PMID: 35418172 PMCID: PMC9009012 DOI: 10.1186/s41927-022-00252-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/09/2022] [Indexed: 11/23/2022] Open
Abstract
Background Rheumatoid arthritis (RA) is a heterogeneous disease with established poor prognostic factors such as seropositivity, joint damage, and high disease activity at an early, treatment-naïve stage of disease. However, few studies have examined if specific joint locations are correlated with these factors in such a population. This analysis explored the potential correlation of individual swollen and erosive joints with other disease characteristics at baseline and with remission rates in a post-hoc analysis of the Phase III randomized AGREE study. Methods Methotrexate (MTX)-naïve, erosive, RF- and/or ACPA-positive early RA patients (N = 509) were retrospectively evaluated. Baseline joint swelling was analyzed for large and small joints. Baseline erosions were analyzed for wrist, MCP1–5, IP1, PIP2–5 and MTP1–5. Remission rates were assessed after 6 months of treatment with abatacept (ABA) + MTX (N = 256) or MTX (N = 253). The following statistical tests were used: Chi-Square or Fisher’s exact test (categorical variables); Student’s t-test or Wilcoxon rank-sum test (continuous variables); continuity-corrected Chi-square test (efficacy remission endpoints). Results Baseline swelling was most frequent in wrist (91.9%) and MCP2 joint (89.1%), while baseline erosion was most frequent in MTP5 joint (43.5%). Swollen shoulder was significantly correlated (p < 0.0001) with swelling of almost all other large or medium joints. Baseline swelling in the knee, temporomandibular joint (TMJ), wrist and elbow was highly correlated (p < 0.001) with higher tender and swollen joint counts, higher DAS28(CRP) and higher SDAI and CDAI. Baseline swelling was not correlated with erosion per joint, except for MCP2. The largest difference in mean Boolean remission rates at 6 months was in patients with baseline swollen wrist favoring ABA + MTX (14.0% vs 4.4%; p < 0.001). Conclusions Swelling in the large and medium joints (knee, TMJ, elbow and wrist) was highly correlated with severe disease activity while MCP2 swelling seemed to be correlated with joint damage. The correlation of joint locations at an early, treatment-naïve stage with poor prognostic factors, higher disease activity and joint damage, could establish a rapidly progressing anatomical pattern in early RA. Trial registration: ClinicalTrials.gov NCT00122382, registered July 2005. Supplementary Information The online version contains supplementary material available at 10.1186/s41927-022-00252-4.
Collapse
Affiliation(s)
- Patrick Durez
- Institut de Recherche Expérimentale Et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Service de rhumatologie, 1200, Bruxelles, Belgium.
| | - Rene Westhovens
- Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
| | - Femke Baeke
- Bristol-Myers Squibb, Braine L'Alleud, Belgium
| | | | | | | |
Collapse
|
6
|
Ozasa R, Matsugaki A, Ishimoto T, Kamura S, Yoshida H, Magi M, Matsumoto Y, Sakuraba K, Fujimura K, Miyahara H, Nakano T. Bone fragility via degradation of bone quality featured by collagen/apatite micro-arrangement in human rheumatic arthritis. Bone 2022; 155:116261. [PMID: 34826630 DOI: 10.1016/j.bone.2021.116261] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 11/15/2021] [Accepted: 11/16/2021] [Indexed: 12/20/2022]
Abstract
Although increased bone fragility is a well-recognized consequence in patients with rheumatoid arthritis (RA), the essential cause of degenerate bone strength remains unknown. This study aimed to determine factors contributing to bone dysfunction in RA by focusing on the bone matrix micro-arrangement, based on the preferential orientation of collagen and the related apatite c-axis as a bone quality index. The classical understanding of RA is limited to its severe pathological conditions associated with inflammation-induced bone loss. This study examined periarticular proximal tibiae from RA patients as compared with osteoarthritis (OA) patients as controls. Bone tissue material strength was disrupted in the RA group compared with the control. Collagen/apatite micro-arrangement and vBMD were significantly lower in the RA group, and the rate of decrease in apatite c-axis orientation (-45%) was larger than that in vBMD (-22%). Multiple regression analysis showed that the degree of apatite c-axis orientation (β = 0.52, p = 1.9 × 10-2) significantly contributed to RA-induced bone material impairment as well as vBMD (β = 0.46, p = 3.8 × 10-2). To the best of our knowledge, this is the first report to demonstrate that RA reduces bone material strength by deteriorating the micro-arrangement of collagen/apatite bone matrix, leading to decreased fracture resistance. Our findings represent the significance of bone quality-based analysis for precise evaluation and subsequent therapy of the integrity and soundness of the bone in patients with RA.
Collapse
Affiliation(s)
- Ryosuke Ozasa
- Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Aira Matsugaki
- Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Takuya Ishimoto
- Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Satoshi Kamura
- Department of Orthopaedic Surgery, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyouhama chuo-ku, Fukuoka, Fukuoka 811-1395, Japan
| | - Hiroto Yoshida
- Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan
| | - Mayu Magi
- Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan
| | - Yoshihiro Matsumoto
- Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan
| | - Koji Sakuraba
- Department of Orthopaedic Surgery, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyouhama chuo-ku, Fukuoka, Fukuoka 811-1395, Japan
| | - Kenjiro Fujimura
- Department of Orthopaedic Surgery, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyouhama chuo-ku, Fukuoka, Fukuoka 811-1395, Japan
| | - Hisaaki Miyahara
- Department of Orthopaedic Surgery, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyouhama chuo-ku, Fukuoka, Fukuoka 811-1395, Japan
| | - Takayoshi Nakano
- Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
| |
Collapse
|
7
|
Fritsche M, Okun M, Kirby JS. Damage in Hidradenitis Suppurativa: A Narrative Review Emphasizing the Need for a Novel Outcome Measure. Br J Dermatol 2022; 187:288-294. [PMID: 35104363 DOI: 10.1111/bjd.21043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 01/25/2022] [Accepted: 01/30/2022] [Indexed: 12/01/2022]
Abstract
Cutaneous damage caused by hidradenitis suppurativa is an important contributor to disease burden, independent of active lesions. Outcome measures used to specifically assess damage are becoming commonplace in assessment of inflammatory diseases. However, no standardized method for assessing HS damage currently exists. The purpose of this study was to review outcome measures in HS that include constructs of both active disease and damage, review damage-specific instruments used in other inflammatory and destructive diseases, and review instruments used to assess scars of various etiologies. This ultimately provides insight into how attributes of different tools can be applied to develop an outcome measure specific to HS damage.
Collapse
Affiliation(s)
| | | | - Joslyn S Kirby
- Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, 17033, USA
| |
Collapse
|
8
|
Rodriguez-García SC, Montes N, Ivorra-Cortes J, Triguero-Martinez A, Rodriguez-Rodriguez L, Castrejón I, Carmona L, González-Álvaro I. Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression. Front Med (Lausanne) 2021; 8:669688. [PMID: 34136506 PMCID: PMC8200542 DOI: 10.3389/fmed.2021.669688] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 04/30/2021] [Indexed: 01/10/2023] Open
Abstract
Objective: To compare the capacity of various disease activity indices to evaluate changes in function, IL-6 levels, and radiographic progression in early and established rheumatoid arthritis (RA). Methods: Secondary data analysis of a clinical trial assessing the efficacy of tocilizumab in patients with established RA (ACT-RAY) and a longitudinal prospective register of early arthritis (PEARL). Targeted outcomes were changes in physical function, measured with the health assessment questionnaire (HAQ), IL-6 serum levels, and radiographic progression. The "Hospital Universitario La Princesa Index" (HUPI), DAS28 using erythrocyte sedimentation rate and SDAI were the disease activity indices compared. Models adjusted for age and sex were fitted for each outcome and index and ranked based on the R 2 parameter and the quasi-likelihood under the independence model criterion. Results: Data from 8,090 visits (550 patients) from ACT-RAY and 775 visits (534 patients) from PEARL were analyzed. The best performing models for HAQ were the HUPI (R 2 = 0.351) and SDAI ones (R 2 = 0.329). For serum IL-6 levels, the SDAI (R 2 = 0.208) followed by the HUPI model (R 2 = 0.205). For radiographic progression in ACT-RAY, the HUPI (R 2 = 0.034) and the DAS28 models (R 2 = 0.026) performed best whereas the DAS28 (R 2 = 0.030) and HUPI models (R 2 = 0.023) did so in PEARL. Conclusions: HUPI outperformed other indices identifying changes in HAQ and radiographic progression and performed similarly to SDAI for IL-6 serum levels.
Collapse
Affiliation(s)
- Sebastián C Rodriguez-García
- Rheumatology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria - Instituto Princesa (IIS-IP), Madrid, Spain
| | - Nuria Montes
- Rheumatology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria - Instituto Princesa (IIS-IP), Madrid, Spain
| | - José Ivorra-Cortes
- Rheumatology Department, Hospital Universitario y Politécnico La Fé, Valencia, Spain
| | - Ana Triguero-Martinez
- Rheumatology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria - Instituto Princesa (IIS-IP), Madrid, Spain
| | - Luis Rodriguez-Rodriguez
- Rheumatology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdiSSC), Madrid, Spain
| | - Isabel Castrejón
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Loreto Carmona
- Instituto de Investigación Músculo-Esquelética (InMusc), Madrid, Spain
| | - Isidoro González-Álvaro
- Rheumatology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria - Instituto Princesa (IIS-IP), Madrid, Spain
| |
Collapse
|
9
|
Kato K, Sutherland K, Tanaka Y, Kato M, Fukae J, Tanimura K, Kamishima T. Fully automatic quantitative software for assessment of minute finger joint space narrowing progression on radiographs: evaluation in rheumatoid arthritis patients with long-term sustained clinical low disease activity. Jpn J Radiol 2020; 38:979-986. [PMID: 32488501 DOI: 10.1007/s11604-020-00996-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Accepted: 05/28/2020] [Indexed: 12/25/2022]
Abstract
PURPOSE Rheumatoid arthritis (RA) causes joint space narrowing (JSN) as a form of joint destruction. We developed an automatic system that can detect joint locations and compute the joint space difference index (JSDI), which was defined as the chronological change in JSN between two radiographs. This study aims to evaluate the application of "machine vision" for radiographic image of the finger joints. MATERIALS AND METHODS Fifteen RA patients with long-term sustained clinical low disease activity were recruited. All patients underwent hand radiography and power Doppler ultrasonography (PDUS). The JSN was evaluated using the Genant-modified Sharp scoring (GSS) method and the automatic system. Synovial vascularity (SV) was assessed quantitatively using ultrasonography. RESULTS There were no significant differences in the JSDI between the joints with JSN and those without JSN on GSS (p = 0.052). The JSDI of the joints with SV was significantly higher than those without SV (p = 0.043). The JSDI of the no therapeutic response group was significantly higher than those of the response group (p < 0.001). CONCLUSION Our software can automatically evaluate temporal changes of JSN, which might free rheumatologists / radiologists from the burden of scoring hand radiography.
Collapse
Affiliation(s)
- Kazuki Kato
- Radiation Department, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan
| | - Kenneth Sutherland
- Global Center for Biomedical Science and Engineering, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan
| | - Yuki Tanaka
- Graduate School of Health Sciences, Hokkaido University, North 12 West 5, Kita-ku, Sapporo, 060-0812, Japan
| | - Masaru Kato
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo, 060-8638, Japan
| | - Jun Fukae
- Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Kotoni 1-3, Nishi-ku, Sapporo, 063-0811, Japan
| | - Kazuhide Tanimura
- Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Kotoni 1-3, Nishi-ku, Sapporo, 063-0811, Japan
| | - Tamotsu Kamishima
- Faculty of Health Sciences, Hokkaido University, North-12 West-5, Kita-ku, Sapporo, 060-0812, Japan.
| |
Collapse
|
10
|
Kato K, Yasojima N, Tamura K, Ichikawa S, Sutherland K, Kato M, Fukae J, Tanimura K, Tanaka Y, Okino T, Lu Y, Kamishima T. Detection of Fine Radiographic Progression in Finger Joint Space Narrowing Beyond Human Eyes: Phantom Experiment and Clinical Study with Rheumatoid Arthritis Patients. Sci Rep 2019; 9:8526. [PMID: 31189913 PMCID: PMC6561904 DOI: 10.1038/s41598-019-44747-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 05/24/2019] [Indexed: 12/12/2022] Open
Abstract
The visual assessment of joint space narrowing (JSN) on radiographs of rheumatoid arthritis (RA) patients such as the Genant-modified Sharp score (GSS) is widely accepted but limited by its subjectivity and insufficient sensitivity. We developed a software application which can assess JSN quantitatively using a temporal subtraction technique for radiographs, in which the chronological change in JSN between two radiographs was defined as the joint space difference index (JSDI). The aim of this study is to prove the superiority of the software in terms of detecting fine radiographic progression in finger JSN over human observers. A micrometer measurement apparatus that can adjust arbitrary joint space width (JSW) in a phantom joint was developed to define true JSW. We compared the smallest detectable changes in JSW between the JSDI and visual assessment using phantom images. In a clinical study, 222 finger joints without interval score change on GSS in 15 RA patients were examined. We compared the JSDI between joints with and without synovial vascularity (SV) on power Doppler ultrasonography during the follow-up period. True JSW difference was correlated with JSDI for JSW differences ranging from 0.10 to 1.00 mm at increments of 0.10 mm (R2 = 0.986 and P < 0.001). Rheumatologists were difficult to detect JSW difference of 0.30 mm or less. The JSDI of finger joints with SV was significantly higher than those without SV (P = 0.030). The software can detect fine differences in JSW that are visually unrecognizable.
Collapse
Affiliation(s)
- Kazuki Kato
- Graduate School of Health Sciences, Hokkaido University, North 12 West 5, Kita-ku, Sapporo, 060-0812, Japan
| | - Nobutoshi Yasojima
- Department of Radiology, NTT Sapporo Medical Center, South 1 West 15, Chuo-ku, Sapporo, 060-0061, Japan
| | - Kenichi Tamura
- Department of Mechanical Engineering, College of Engineering, Nihon University, Tokusada Aza Nakagawara 1, Tamura-cho, Koriyama, 963-8642, Japan
| | - Shota Ichikawa
- Department of Radiological Technology, Kurashiki Central Hospital, Miwa 1, Kurashiki, 710-8602, Japan
| | - Kenneth Sutherland
- Division of Photonic Bioimaging, Faculty of Medicine Research Center for Cooperative Projects, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan
| | - Masaru Kato
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan
| | - Jun Fukae
- Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Kotoni 1-3, Nishi-ku, Sapporo, 063-0811, Japan
| | - Kazuhide Tanimura
- Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Kotoni 1-3, Nishi-ku, Sapporo, 063-0811, Japan
| | - Yuki Tanaka
- Graduate School of Health Sciences, Hokkaido University, North 12 West 5, Kita-ku, Sapporo, 060-0812, Japan
| | - Taichi Okino
- Department of Radiological Technology, Sapporo City General Hospital, North 11 West 13, Chuo-ku, Sapporo, 060-8604, Japan
| | - Yutong Lu
- Faculty of Health Sciences, Hokkaido University, North-12 West-5, Kita-ku, Sapporo, 060-0812, Japan
| | - Tamotsu Kamishima
- Faculty of Health Sciences, Hokkaido University, North-12 West-5, Kita-ku, Sapporo, 060-0812, Japan.
| |
Collapse
|
11
|
Rubin DA. MRI and ultrasound of the hands and wrists in rheumatoid arthritis. I. Imaging findings. Skeletal Radiol 2019; 48:677-695. [PMID: 30796506 DOI: 10.1007/s00256-019-03179-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 01/19/2019] [Accepted: 02/03/2019] [Indexed: 02/02/2023]
Abstract
The management of patients with rheumatoid arthritis (RA) has rapidly evolved with the development of newer disease-modifying drugs and the recognition that long-term damage can be mitigated by an earlier and more-informed use of these medications. Historically, radiographs were the mainstay of imaging in RA patients, but radiographic joint narrowing and erosions are late and insensitive findings in the disease. MRI (with intravenous contrast agent) and ultrasound (with power Doppler interrogation) of the hands and wrists are able to demonstrate erosions earlier and with greater sensitivity than radiographs. More importantly, these imaging studies also depict synovitis and active soft-tissue inflammation, which represents a precursor to structural damage. Additionally, MRI can show inflammation within the bones (osteitis), which is proving to be the most important prognosticator of an aggressive disease course. Part I of this review discusses the imaging techniques, pitfalls, definitions, and comparative studies of MRI and ultrasound for identifying and quantifying erosions, synovitis, and osteitis. Part II will demonstrate how these imaging findings influence the clinical management of RA patients throughout their disease course, from presentation through clinical remission.
Collapse
Affiliation(s)
- David A Rubin
- Department of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, MO, 63110, USA.
| |
Collapse
|
12
|
Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M. Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. Semin Arthritis Rheum 2019; 49:218-221. [PMID: 30878153 DOI: 10.1016/j.semarthrit.2019.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 02/07/2019] [Accepted: 02/18/2019] [Indexed: 11/25/2022]
Abstract
INTRODUCTION The distribution of progression scores in rheumatoid arthritis is highly skewed, requiring advanced statistical analysis techniques, with different techniques resulting in different outcomes. METHODS Three databases were searched to identify rheumatoid arthritis clinical trials and observational studies that described radiographic analysis techniques, comparing at least two groups. RESULTS Of 5980 identified papers, 225 were eligible for data extraction. Parametric techniques (t-tests, ANOVA or linear regression) were used in 39 studies, of which 18% took the skewed distribution into account. In 53 studies, continuous data was categorized and analyzed with binomial or ordinal methods (chi-square tests or logistic regression). Two studies treated the outcome as a 'count' outcome variable (applying a Poisson). CONCLUSION There is large heterogeneity in the analysis strategy of radiographic progression in recent rheumatoid arthritis clinical trials and observational studies, with the majority of studies applying simple, suboptimal or inappropriate methods.
Collapse
Affiliation(s)
- Sehrash Mahmood
- Amsterdam Rheumatology and Immunology Center, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
| | - Lilian van Tuyl
- Amsterdam Rheumatology and Immunology Center, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
| | - Linda J Schoonmade
- Medical Library, VU University, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
| | - Robert Landewé
- Amsterdam Rheumatology and immunology Center, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands
| | - Désirée van der Heijde
- Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | - Jos Twisk
- Department of Epidemiology & Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
| | - Maarten Boers
- Department of Epidemiology & Biostatistics, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
| |
Collapse
|
13
|
Salama SM. Comparison between the roles of musculoskeletal ultrasound and magnetic resonance imaging in detection of joint inflammation and destruction in rheumatoid arthritis. EGYPTIAN RHEUMATOLOGY AND REHABILITATION 2018. [DOI: 10.4103/1110-161x.247617] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
14
|
Fukae J, Tanimura K, Isobe M, Kitano A, Henmi M, Nakai M, Aoki Y, Sakamoto F, Narita A, Ito T, Mitsuzaki A, Matsuhashi M, Shimizu M, Kamishima T, Atsumi T, Koike T. Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment. Int J Rheum Dis 2018; 21:1809-1814. [DOI: 10.1111/1756-185x.13030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jun Fukae
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | | | - Masato Isobe
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Akemi Kitano
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Mihoko Henmi
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Maria Nakai
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Yuko Aoki
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | | | - Akihiro Narita
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Takeya Ito
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | - Akio Mitsuzaki
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | | | - Masato Shimizu
- Hokkaido Medical Center for Rheumatic Diseases; Sapporo Japan
| | | | - Tatsuya Atsumi
- Department of Medicine II; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - Takao Koike
- Department of Medicine II; Hokkaido University Graduate School of Medicine; Sapporo Japan
| |
Collapse
|
15
|
Computer-Based Radiographic Quantification of Joint Space Narrowing Progression Using Sequential Hand Radiographs: Validation Study in Rheumatoid Arthritis Patients from Multiple Institutions. J Digit Imaging 2018; 30:648-656. [PMID: 28378032 DOI: 10.1007/s10278-017-9970-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We have developed a refined computer-based method to detect joint space narrowing (JSN) progression with the joint space narrowing progression index (JSNPI) by superimposing sequential hand radiographs. The purpose of this study is to assess the validity of a computer-based method using images obtained from multiple institutions in rheumatoid arthritis (RA) patients. Sequential hand radiographs of 42 patients (37 females and 5 males) with RA from two institutions were analyzed by a computer-based method and visual scoring systems as a standard of reference. The JSNPI above the smallest detectable difference (SDD) defined JSN progression on the joint level. The sensitivity and specificity of the computer-based method for JSN progression was calculated using the SDD and a receiver operating characteristic (ROC) curve. Out of 314 metacarpophalangeal joints, 34 joints progressed based on the SDD, while 11 joints widened. Twenty-one joints progressed in the computer-based method, 11 joints in the scoring systems, and 13 joints in both methods. Based on the SDD, we found lower sensitivity and higher specificity with 54.2 and 92.8%, respectively. At the most discriminant cutoff point according to the ROC curve, the sensitivity and specificity was 70.8 and 81.7%, respectively. The proposed computer-based method provides quantitative measurement of JSN progression using sequential hand radiographs and may be a useful tool in follow-up assessment of joint damage in RA patients.
Collapse
|
16
|
Ishikawa K, Ishikawa J. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol 2018; 29:418-429. [DOI: 10.1080/14397595.2018.1481565] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
17
|
AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis. Int J Rheumatol 2018; 2018:8721753. [PMID: 29849651 PMCID: PMC5925169 DOI: 10.1155/2018/8721753] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 02/13/2018] [Accepted: 02/26/2018] [Indexed: 11/21/2022] Open
Abstract
Aim Examine the efficacy of once-weekly subcutaneous tocilizumab (SC-TCZ) on joint damage at 24 weeks based on radiography of the hands and feet and magnetic resonance imaging (MRI) of the hand in subjects with moderate to severe rheumatoid arthritis (RA). Methods In this Australian open-label, multicentre, prospective, single-arm study, subjects received 162 mg SC-TCZ weekly. Primary endpoint was change in radiographic Genant-modified Total Sharp Score (TSS) between baseline and Week 24. Secondary endpoints included change from baseline to Week 24 in RA MRI scoring (RAMRIS) of erosions, synovitis, and osteitis and Cartilage Loss Score (CARLOS) in the dominant hand and disease activity score 28 (DAS28). Results 52 subjects were enrolled (80% female, mean (SD) age 57 (12) years). Radiography showed mild but not significant progression of joint damage (mean (SD) change in TSS 0.46 (1.29)). Synovitis reduced significantly on MRI; however, osteitis, erosion, and cartilage loss did not change significantly. DAS28 improved significantly by Week 24; 78% of subjects achieved DAS28 remission. SC-TCZ was generally well tolerated. Conclusion Synovitis and DAS28 decreased significantly; however, no significant change in osteitis or joint damage was observed at Week 24. Trial registration This trial is registered with Clinicaltrials.gov registration number NCT01951170 (ML28703).
Collapse
|
18
|
Leijten EFA, Radstake TRDJ, Reedquist KA. Editorial: Lessons Learned From a "Failed" Clinical Trial. Arthritis Rheumatol 2018; 70:1364-1365. [PMID: 29669390 DOI: 10.1002/art.40526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 04/10/2018] [Indexed: 12/15/2022]
Affiliation(s)
- E F A Leijten
- University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - K A Reedquist
- University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
19
|
Okino T, Kamishima T, Lee Sutherland K, Fukae J, Narita A, Ichikawa S, Tanimura K. Radiographic temporal subtraction analysis can detect finger joint space narrowing progression in rheumatoid arthritis with clinical low disease activity. Acta Radiol 2018; 59:460-467. [PMID: 28728431 DOI: 10.1177/0284185117721262] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Recent papers suggest that finger joints with positive synovial vascularity (SV) assessed by ultrasonography under clinical low disease activity (CLDA) in rheumatoid arthritis (RA) patients may cause joint space narrowing (JSN) progression. Purpose To investigate the performance of a computer-based method by directly comparing with the conventional scoring method in terms of the detectability of JSN progression in hand radiography of RA patients with CLDA. Material and Methods Fifteen RA patients (13 women, 2 men) with long-term sustained CLDA of >2 years were included. Radiological progression of finger joints was measured or scored using the computer-based method which can detect JSN progression between two radiographic images as the joint space difference index (JSDI), as well as the Genant-modified Sharp score (GSS). We also quantitatively assessed SV of these joints using ultrasonography. Results Out of 270 joints, we targeted 259 finger joints after excluding nine damaged joints (four ankylosis, three complete luxation, and two subluxation) and two improved joints according to the GSS results. The JSDI of finger joints with JSN progression was significantly higher than those without JSN progression ( P = 0.018). The JSDI of finger joints with ultrasonographic SV was significantly higher than those without ultrasonographic SV ( P = 0.004). Progression in JSDI showed stronger associations with ultrasonographic SV than progression in GSS (odds ratio [95% confidence interval]: 7.19 [3.37-15.36] versus 5.84 [2.76-12.33]). Conclusion The computer-based method was comparable to the conventional scoring method regarding the detectability of JSN progression in RA patients with CLDA.
Collapse
Affiliation(s)
- Taichi Okino
- Department of Radiological Technology, Sapporo City General Hospital, Sapporo, Japan
| | | | | | - Jun Fukae
- Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan
| | - Akihiro Narita
- Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan
| | - Shota Ichikawa
- Department of Radiological Technology, Kurashiki Central Hospital, Kurashiki, Japan
| | | |
Collapse
|
20
|
Simpson E, Hock E, Stevenson M, Wong R, Dracup N, Wailoo A, Conaghan P, Estrach C, Edwards C, Wakefield R. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technol Assess 2018; 22:1-258. [PMID: 29712616 PMCID: PMC5949573 DOI: 10.3310/hta22200] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Synovitis (inflamed joint synovial lining) in rheumatoid arthritis (RA) can be assessed by clinical examination (CE) or ultrasound (US). OBJECTIVE To investigate the added value of US, compared with CE alone, in RA synovitis in terms of clinical effectiveness and cost-effectiveness. DATA SOURCES Electronic databases including MEDLINE, EMBASE and the Cochrane databases were searched from inception to October 2015. REVIEW METHODS A systematic review sought RA studies that compared additional US with CE. Heterogeneity of the studies with regard to interventions, comparators and outcomes precluded meta-analyses. Systematic searches for studies of cost-effectiveness and US and treatment-tapering studies (not necessarily including US) were undertaken. MATHEMATICAL MODEL A model was constructed that estimated, for patients in whom drug tapering was considered, the reduction in costs of disease-modifying anti-rheumatic drugs (DMARDs) and serious infections at which the addition of US had a cost per quality-adjusted life-year (QALY) gained of £20,000 and £30,000. Furthermore, the reduction in the costs of DMARDs at which US becomes cost neutral was also estimated. For patients in whom dose escalation was being considered, the reduction in number of patients escalating treatment and in serious infections at which the addition of US had a cost per QALY gained of £20,000 and £30,000 was estimated. The reduction in number of patients escalating treatment for US to become cost neutral was also estimated. RESULTS Fifty-eight studies were included. Two randomised controlled trials compared adding US to a Disease Activity Score (DAS)-based treat-to-target strategy for early RA patients. The addition of power Doppler ultrasound (PDUS) to a Disease Activity Score 28 joints-based treat-to-target strategy in the Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) trial resulted in no significant between-group difference for change in Disease Activity Score 44 joints (DAS44). This study found that significantly more patients in the PDUS group attained DAS44 remission (p = 0.03). The Aiming for Remission in Rheumatoid Arthritis (ARCTIC) trial found that the addition of PDUS and grey-scale ultrasound (GSUS) to a DAS-based strategy did not produce a significant between-group difference in the primary end point: composite DAS of < 1.6, no swollen joints and no progression in van der Heijde-modified total Sharp score (vdHSS). The ARCTIC trial did find that the erosion score of the vdHS had a significant advantage for the US group (p = 0.04). In the TaSER trial there was no significant group difference for erosion. Other studies suggested that PDUS was significantly associated with radiographic progression and that US had added value for wrist and hand joints rather than foot and ankle joints. Heterogeneity between trials made conclusions uncertain. No studies were identified that reported the cost-effectiveness of US in monitoring synovitis. The model estimated that an average reduction of 2.5% in the costs of biological DMARDs would be sufficient to offset the costs of 3-monthly US. The money could not be recouped if oral methotrexate was the only drug used. LIMITATIONS Heterogeneity of the trials precluded meta-analysis. Therefore, no summary estimates of effect were available. Additional costs and health-related quality of life decrements, relating to a flare following tapering or disease progression, have not been included. The feasibility of increased US monitoring has not been assessed. CONCLUSION Limited evidence suggests that US monitoring of synovitis could provide a cost-effective approach to selecting RA patients for treatment tapering or escalation avoidance. Considerable uncertainty exists for all conclusions. Future research priorities include evaluating US monitoring of RA synovitis in longitudinal clinical studies. STUDY REGISTRATION This study is registered as PROSPERO CRD42015017216. FUNDING The National Institute for Health Research Health Technology Assessment programme.
Collapse
Affiliation(s)
- Emma Simpson
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Emma Hock
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Matt Stevenson
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Ruth Wong
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Naila Dracup
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Allan Wailoo
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Philip Conaghan
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK
| | - Cristina Estrach
- Aintree University Hospitals NHS Foundation Trust, Liverpool, UK
| | - Christopher Edwards
- National Institute for Health Research (NIHR) Wellcome Trust Clinical Research Facility, University of Southampton, Southampton, UK
| | - Richard Wakefield
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK
| |
Collapse
|
21
|
Yasui T, Oka H, Omata Y, Kadono Y, Tanaka S. Relationship between roentgenographic joint destruction in the hands and functional disorders among patients with rheumatoid arthritis. Mod Rheumatol 2016; 27:828-832. [PMID: 27830955 DOI: 10.1080/14397595.2016.1254361] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVES Although a relationship between joint destruction and functional disorders seems apparent in patients with rheumatoid arthritis (RA), it has not been well proven in the literature. The aims of this study were to clarify the relationship between roentgenographic joint destruction in the hands and functional disorders in patients with RA, and to explore the appropriate assessment measures for functional disorders. METHODS Cross-sectional data of the Genant-modified Total Sharp Score (Genant-mTSS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Disabilities of the Arm, Shoulder, and Hand (DASH), and Michigan Hand Outcomes Questionnaire (MHQ) were collected from 50 consecutive RA patients and analyzed. RESULTS HAQ-DI, DASH, and MHQ had close correlations with Genant-mTSS, with correlation coefficients of 0.69, 0.71, and -0.70, respectively, among patients with low disease activity (DAS28 < 3.2). A floor effect was observed in HAQ-DI, but neither floor nor ceiling effects were observed in DASH and MHQ. Both DASH and MHQ were strongly correlated with HAQ-DI, with correlation coefficients of 0.87 and 0.73, respectively. CONCLUSIONS Functional disorders had significant relationships with roentgenographic joint destruction in the hands among RA patients with low disease activity. As assessment measures of functional disorders, DASH and MHQ had no floor or ceiling effects, being different from HAQ-DI.
Collapse
Affiliation(s)
- Tetsuro Yasui
- a Department of Orthopaedic Surgery, Faculty of Medicine , The University of Tokyo , Tokyo , Japan.,b Department of Orthopaedic Surgery , Teikyo University Mizonokuchi Hospital , Kanagawa , Japan
| | - Hiroyuki Oka
- c Department of Medical Research and Management for Musculoskeletal Pain , 22nd Century Medical & Research Center, Faculty of Medicine, The University of Tokyo , Tokyo , Japan , and
| | - Yasunori Omata
- a Department of Orthopaedic Surgery, Faculty of Medicine , The University of Tokyo , Tokyo , Japan
| | - Yuho Kadono
- d Department of Orthopaedic Surgery , Saitama Medical University , Saitama , Japan
| | - Sakae Tanaka
- a Department of Orthopaedic Surgery, Faculty of Medicine , The University of Tokyo , Tokyo , Japan
| |
Collapse
|
22
|
Buch MH, Hensor EMA, Rakieh C, Freeston JE, Middleton E, Horton S, Das S, Peterfy C, Tan AL, Wakefield RJ, Emery P. Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. Rheumatology (Oxford) 2016; 56:58-67. [DOI: 10.1093/rheumatology/kew357] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 04/18/2016] [Indexed: 11/14/2022] Open
|
23
|
Huo Y, Vincken KL, van der Heijde D, De Hair MJH, Lafeber FP, Viergever MA. Automatic Quantification of Radiographic Finger Joint Space Width of Patients With Early Rheumatoid Arthritis. IEEE Trans Biomed Eng 2016; 63:2177-86. [DOI: 10.1109/tbme.2015.2512941] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
24
|
Koh JH, Myong JP, Jung SM, Lee J, Kwok SK, Park SH, Ju JH. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study. Arthritis Rheumatol 2016; 68:77-82. [PMID: 26360133 DOI: 10.1002/art.39429] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Accepted: 09/03/2015] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To examine the clinical characteristics of atypical femoral fracture (AFF) and to determine the risk factors for and clinical outcomes of AFFs in rheumatoid arthritis (RA) patients treated with bisphosphonates (BPs). METHODS A nested case-control study was conducted using data derived from the medical records of all RA patients treated with BPs at Seoul St. Mary's Hospital, a tertiary rheumatology center, from January 1, 2008 to December 31, 2014. All of the patients with RA and had been treated with BPs for at least 1 year. Ten RA patients with AFF were identified, and each of these patients (cases) was age- and sex-matched with 4 RA patients without AFF (controls). RESULTS Five hundred fifty-two RA patients had BP exposure. Of the 10 with AFF, all were female (mean ± SD age 66.3 ± 8.7 years), and 90% of cases involved fracture of the proximal femur. The mean ± SD length of BP exposure in patients with AFF was 7.4 ± 3.2 years. Compared with controls, patients with AFF had a longer exposure to BPs and more often had a femorotibial angle of <175 degrees (both P < 0.001). There were no differences in RA duration, medications taken during the previous 6 months, and bone mineral density in the femur and lumbar spine between patients with and those without AFF. Multivariate logistic analyses identified longer BP exposure (odds ratio 2.386 [95% confidence interval 1.066-5.343]) as being associated with an increased risk of AFF. CONCLUSION RA patients who have a valgus deformity and are receiving long-term BP treatment are at higher risk of AFF compared with matched control patients with RA. These patients should be carefully followed up with hip radiography or dual x-ray absorptiometry.
Collapse
Affiliation(s)
- Jung Hee Koh
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Jun Pyo Myong
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Seung Min Jung
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Jennifer Lee
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Seung-Ki Kwok
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Sung-Hwan Park
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| | - Ji Hyeon Ju
- Seoul St. Mary's Hospital and Catholic University of Korea, Seoul, Republic of Korea
| |
Collapse
|
25
|
|
26
|
Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EMA, Emery P, Buch MH. A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). BMC Musculoskelet Disord 2016; 17:61. [PMID: 26847108 PMCID: PMC4743173 DOI: 10.1186/s12891-016-0915-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 02/02/2016] [Indexed: 12/05/2022] Open
Abstract
Background Rheumatoid arthritis (RA) is a chronic inflammatory arthritis, with significant impact on quality of life and functional status. Whilst biologic disease modifying anti-rheumatic drugs (bDMARD) such as tumour necrosis factor-inhibitor (TNFi) agents have revolutionised outcomes in RA, early diagnosis with immediate conventional therapy, titrated in a treat to target approach is also associated with high remission rates. The main aim of the VEDERA study (Very Early versus Delayed Etanercept in Rheumatoid Arthritis) is to assess the depth of remission, sustainability of remission and immunological normalisation induced by very early TNFi with etanercept (ETN) or standard of care +/- delayed ETN. Methods/Design VEDERA is a pragmatic, phase IV single-centre open-label randomised superiority trial of 120 patients with early, treatment-naive RA. Patients will be randomised 1:1 to first-line ETN and methotrexate (MTX) or MTX with additional synthetic disease modifying anti-rheumatic drugs (sDMARDs) according to a treat to target (TT) protocol with further step up to ETN and MTX after 24 weeks if remission is not achieved. Participants will have regular disease activity assessments and imaging evaluation including musculoskeletal ultrasound and MRI. The main objective of this study is to assess the proportion of patients with early RA that achieve clinical remission at 48 weeks, following either treatment strategy. In addition, the participants are invited to take part in a cardio-vascular sub-study (Coronary Artery Disease in RA, CADERA), which aims to identify the incidence of cardiovascular abnormalities in early RA. Discussion The hypothesis underlining this study is that very early treatment with first-line ETN increases the proportion of patients with rheumatoid arthritis achieving clinical remission, in comparison to conventional therapy. Trial registration NCT02433184, 23/04/2015
Collapse
Affiliation(s)
- Raluca B Dumitru
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Sarah Horton
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Richard Hodgson
- University of Manchester Centre for Imaging Sciences, Manchester, UK
| | - Richard J Wakefield
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Elizabeth M A Hensor
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Paul Emery
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Maya H Buch
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. .,NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
| |
Collapse
|
27
|
Grassi W, Okano T, Di Geso L, Filippucci E. Imaging in rheumatoid arthritis: options, uses and optimization. Expert Rev Clin Immunol 2015; 11:1131-46. [DOI: 10.1586/1744666x.2015.1075395] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
28
|
Watanabe T, Takase-Minegishi K, Ihata A, Kunishita Y, Kishimoto D, Kamiyama R, Hama M, Yoshimi R, Kirino Y, Asami Y, Suda A, Ohno S, Tateishi U, Ueda A, Takeno M, Ishigatsubo Y. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol 2015; 26:180-7. [PMID: 26140472 DOI: 10.3109/14397595.2015.1069458] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
OBJECTIVE To compare the findings in rheumatoid arthritis (RA)-affected joints between (18)F-fluorodeoxyglucose (FDG) and (18)F-fluoride (NaF) positron emission tomography (PET)/computed tomography (CT). METHODS We enrolled twelve RA patients who started a new biologic agent (naïve 9 and switch 3). At entry, both hands were examined by (18)F-FDG PET/CT, (18)F-NaF PET/CT, and X-ray. Intensity of PET signals was determined by standardized uptake value max (SUVmax) in metacarpophalangeal (MCP), proximal interphalangeal (PIP), and ulnar, medial, and radial regions of the wrists. Hand X-rays were evaluated according to the Genant-modified Sharp score at baseline and 6 months. RESULTS Both (18)F-FDG and (18)F-NaF accumulated in RA-affected joints. The SUVmax of (18)F-FDG correlated with that of (18)F-NaF in individual joints (r = 0.65), though detail distribution was different between two tracers. (18)F-NaF and (18)F-FDG signals were mainly located in the bone and the surrounding soft tissues, respectively. The sum of SUVmax of (18)F-NaF correlated with disease activity score in 28 joint (DAS28), modified health assessment questionnaire (MHAQ), and radiographic progression. (18)F-FDG and (18)F-NaF signals were associated with the presence of erosions, particularly progressive ones. CONCLUSION Our data show that both (18)F-FDG and (18)F-NaF PET signals were associated with RA-affected joints, especially those with ongoing erosive changes.
Collapse
Affiliation(s)
- Toshiyuki Watanabe
- a Center for Rheumatic disease, Yokohama City University Medical Center , Yokohama , Japan
| | - Kaoru Takase-Minegishi
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Atsushi Ihata
- c Department of Rheumatology and Infectious disease , Yokohama Minami Kyosai Hospital , Yokohama , Japan
| | - Yosuke Kunishita
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Daiga Kishimoto
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Reikou Kamiyama
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Maasa Hama
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Ryusuke Yoshimi
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Yohei Kirino
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Yukiko Asami
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Akiko Suda
- a Center for Rheumatic disease, Yokohama City University Medical Center , Yokohama , Japan
| | - Shigeru Ohno
- a Center for Rheumatic disease, Yokohama City University Medical Center , Yokohama , Japan
| | - Ukihide Tateishi
- d Department of Radiology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Atsuhisa Ueda
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Mitsuhiro Takeno
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| | - Yoshiaki Ishigatsubo
- b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan
| |
Collapse
|
29
|
Lu MC, Yu CL, Yu HC, Huang HB, Koo M, Lai NS. Anti-citrullinated protein antibodies promote apoptosis of mature human Saos-2 osteoblasts via cell-surface binding to citrullinated heat shock protein 60. Immunobiology 2015; 221:76-83. [PMID: 26275591 DOI: 10.1016/j.imbio.2015.07.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 07/21/2015] [Accepted: 07/23/2015] [Indexed: 01/12/2023]
Abstract
We hypothesized that anti-citrullinated protein antibodies (ACPAs) react with osteoblast surface citrullinated proteins and affect cell function, leading to joint damage in patients with rheumatoid arthritis (RA). First, we purified ACPAs by cyclic citrullinated peptide (CCP)-conjugated affinity column chromatography. The cognate antigens of ACPAs on Saos-2 cells, a sarcoma osteogenic cell line generated from human osteoblasts, were probed by ACPAs, and the reactive bands were analyzed using proteomic analyses. We found that ACPAs bind to Saos-2 cell membrane, and several protein candidates, including HSP60, were identified. We then cloned and purified recombinant heat shock protein 60 (HSP60) and citrullinated HSP60 (citHSP60) and investigated the effect of ACPAs on Saos-2 cell. We confirmed that HSP60 obtained from Saos-2 cell membrane were citrullinated and reacted with ACPAs, which induces Saos-2 cells apoptosis via binding to surface-expressed citHSP60 through Toll-like receptor 4 signaling. ACPAs promoted interleukin (IL)-6 and IL-8 expression in Saos-2 cells. Finally, sera from patients with RA and healthy controls were examined for their titers of anti-HSP60 and anti-citHSP60 antibodies using an enzyme-linked immunosorbent assay. The radiographic change in patients with RA was evaluated using the Genant-modified Sharp scoring system. Patients with RA showed higher sera titers of anti-citHSP60, but not anti-HSP60, antibodies when compared with controls. In addition, the anti-citHSP60 level was positively associated with increased joint damage in patients with RA. In conclusion, Saos-2 cell apoptosis was mediated by ACPAs via binding to cell surface-expressed citHSP60 and the titer of anti-citHSP60 in patients with RA positively associated with joint damage.
Collapse
Affiliation(s)
- Ming-Chi Lu
- Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan; School of Medicine, Tzu Chi University, Hualien, Taiwan
| | - Chia-Li Yu
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - Hui-Chun Yu
- Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
| | - Hsien-Bin Huang
- Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan
| | - Malcolm Koo
- Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan; Dalla Lana School of Public Health, University of Toronto, Ontario, Canada
| | - Ning-Sheng Lai
- Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan; School of Medicine, Tzu Chi University, Hualien, Taiwan.
| |
Collapse
|
30
|
Smolen JS, Wollenhaupt J, Gomez-Reino JJ, Grassi W, Gaillez C, Poncet C, Le Bars M, Westhovens R. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther 2015; 17:157. [PMID: 26063454 PMCID: PMC4494702 DOI: 10.1186/s13075-015-0671-9] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Accepted: 06/02/2015] [Indexed: 12/19/2022] Open
Abstract
INTRODUCTION This study evaluated various remission criteria in abatacept plus methotrexate (MTX)-treated patients with early rheumatoid arthritis (RA). We aimed to investigate the time to, and sustainability of, remission, and to evaluate the relationship between remission, function and structure. METHODS Post hoc analyses were performed from the 12-month, double-blind period of the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE) in patients with early RA (≤2 years) and poor prognostic factors, comparing abatacept plus MTX (n = 210) versus MTX alone (n = 209). RESULTS At month 12, Disease Activity Score 28, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index and Boolean remission rates were, for abatacept plus MTX versus MTX alone: 47.6 % versus 27.3 %, 33.3 % versus 12.4 %, 34.3 % versus 16.3 %, and 23.8 % versus 5.7 %, respectively. Cumulative probability demonstrated higher proportions achieving first remission and first sustained remission for abatacept plus MTX versus MTX alone (e.g., 23.3 % [95 % confidence interval (CI): 17.6, 29.1] vs 12.9 % [8.4, 17.5] for first SDAI remission over 0-6 months). For patients in SDAI remission at month 3, mean Health Assessment Questionnaire-Disability Index at month 12 was 0.20 versus 0.50 for abatacept plus MTX versus MTX alone. Mean changes in radiographic score from baseline to month 12 were minimal for patients in SDAI remission at month 3 in both groups, while less structural damage progression was seen, 0.75 versus 1.35, respectively, for abatacept plus MTX versus MTX alone for patients with moderate/high disease activity at month 3 (adjusted mean treatment difference: -0.60 [95 % CI: -1.11, -0.09; P < 0.05]). CONCLUSIONS High proportions of abatacept plus MTX-treated patients achieved stringent remission criteria. Remission was associated with long-term functional benefit; dissociation was seen between clinical and structural outcomes for abatacept. These findings highlight the impact of reaching stringent remission targets early, on physical function and structural damage, in MTX-naïve biologic-treated patients. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT00122382. Registered 19 July 2005.
Collapse
Affiliation(s)
- Josef S Smolen
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18-20, Vienna, A-1090, Austria.
| | | | | | - Walter Grassi
- Clinica Reumatologica, Università Politecnica delle Marche, Ancona, Italy.
| | | | | | | | - Rene Westhovens
- Skeletal Biology and Engineering Research Center, Department of Development and Regeneration KU Leuven; Rheumatology, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
31
|
OARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritis. Osteoarthritis Cartilage 2015; 23:732-46. [PMID: 25952345 DOI: 10.1016/j.joca.2015.03.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2014] [Revised: 03/04/2015] [Accepted: 03/09/2015] [Indexed: 02/02/2023]
Abstract
Tremendous advances have occurred in our understanding of the pathogenesis of hand osteoarthritis (OA) and these are beginning to be applied to trials targeted at modification of the disease course. The purpose of this expert opinion, consensus driven exercise is to provide detail on how one might use and apply hand imaging assessments in disease modifying clinical trials. It includes information on acquisition methods/techniques (including guidance on positioning for radiography, sequence/protocol recommendations/hardware for MRI); commonly encountered problems (including positioning, hardware and coil failures, sequences artifacts); quality assurance/control procedures; measurement methods; measurement performance (reliability, responsiveness, validity); recommendations for trials; and research recommendations.
Collapse
|
32
|
Snekhalatha U, Anburajan M. Computer-based measurements of joint space analysis using metacarpal morphometry in hand radiograph for evaluation of rheumatoid arthritis. Int J Rheum Dis 2015; 20:1120-1131. [PMID: 25865479 DOI: 10.1111/1756-185x.12559] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIM AND OBJECTIVES The aim and objectives are as follows: (i) to perform an automated segmentation of the hand from radiographs using a dual tree complex wavelet-based watershed algorithm; ii) to compare the measured statistical features of the joint space of the hand using gray level co-occurrence matrix (GLCM) method with standard diagnostic parameters of rheumatoid arthritis (RA). METHODS Fifty-three patients with RA and 17 age- and sex-matched healthy controls were included in the study. The erythrocyte sedimentation rate (ESR), C-reactive protein, rheumatoid factor, health assessment questionnaire score (HAQ), disease activity score (DAS) and hand radiographs of all the subjects were obtained. Joint space width and cortical thickness were measured in metacarpophalangeal joints (MCP) and metacarpal bone semi-automatically using MIMICS software. Dual tree complex wavelet transform-based watershed algorithm was applied for automated segmentation, and feature extraction was performed using the GLCM method in hand radiographs of the total population. RESULTS In the RA group (n = 53), the joint space width measured in the MCP1, MCP3, MCP5 of the hand were reduced significantly (P < 0.01) by 16.4%, 15.6%, and 17.5%, respectively compared to the normal group (n = 17). The measured combined cortical thickness at the second, third and fourth metacarpal bones of the hand were reduced significantly (P < 0.01) by 9.5%, 12% and 8%, respectively in the RA group compared to the normal group. CONCLUSION The dual tree complex wavelet transform-based watershed algorithm provided effective segmentation in the digitized hand radiographs. The standard diagnostic parameters for RA were highly correlated with measured statistical features at MCP3 hand joint in the total population studied.
Collapse
Affiliation(s)
- U Snekhalatha
- Department of Biomedical Engineering, SRM University, Kattankulathur, Chennai, Tamilnadu, India
| | - M Anburajan
- Department of Biomedical Engineering, SRM University, Kattankulathur, Chennai, Tamilnadu, India
| |
Collapse
|
33
|
Abstract
BACKGROUND Rituximab is a selective, B-cell depleting, biologic agent for treating refractory rheumatoid arthritis (RA). It is a chimeric monoclonal antibody targeted against CD 20 that is promoted as therapy for patients who fail to respond to other biologics. There is evidence to suggest that rituximab is effective and well tolerated when used in combination with methotrexate for RA. OBJECTIVES To evaluate the benefits and harms of rituximab for the treatment of RA. SEARCH METHODS We conducted a search (until January 2014) in electronic databases (The Cochrane Library, MEDLINE, EMBASE, CINAHL, Web of Science), clinical trials registries, and websites of regulatory agencies. Reference lists from comprehensive reviews were also screened. SELECTION CRITERIA All controlled trials comparing treatment with rituximab as monotherapy or in combination with any disease modifying anti-rheumatic drug (DMARD) (traditional or biologic) versus placebo or other DMARD (traditional or biologic) in adult patients with active RA. DATA COLLECTION AND ANALYSIS Two review authors independently assessed the risk of bias and abstracted data from each study. MAIN RESULTS We included eight studies with 2720 patients. For six studies selection bias could not be evaluated and two studies were considered to have low risk of bias. The level of evidence ranged from low to high, but was rated as moderate for most outcomes. We have prioritised reporting of rituximab (two 1000 mg doses) in combination with methotrexate since this is the approved dose and most commonly used combination. We also reported data on other combinations and doses as supplementary information in the results section of the review.American College of Rheumatology (ACR) 50 response rates were statistically significantly improved with rituximab (two 1000 mg doses) in combination with methotrexate compared with methotrexate alone at 24 to 104 weeks. The RR for achieving an ACR 50 at 24 weeks was 3.3 (95% CI 2.3 to 4.6); 29% of patients receiving rituximab (two 1000 mg doses) in combination with methotrexate achieved the ACR 50 compared to 9% of controls. The absolute treatment benefit (ATB) was 21% (95% CI 16% to 25%) with a number needed to treat (NNT) of 6 (95% CI 4 to 9).At 52 weeks, the RR for achieving clinical remission (Disease Activity Score (DAS) 28 joints < 2.6) with rituximab (two 1000 mg doses) in combination with methotrexate compared with methotrexate monotherapy was 2.4 (95% CI 1.7 to 3.5); 22% of patients receiving rituximab (two 1000 mg doses) in combination with methotrexate achieved clinical remission compared to 11% of controls. The ATB was 11% (95% CI 2% to 20%) with a NNT of 7 (95% CI 4 to 13).At 24 weeks, the RR for achieving a clinically meaningful improvement (CMI) in the Health Assessment Questionnaire (HAQ) (> 0.22) for patients receiving rituximab combined with methotrexate compared to patients on methotrexate alone was 1.6 (95% CI 1.2 to 2.1). The ATB was 24% (95% CI 12% to 36%) with an NNT of 5 (95% CI 3 to 13). At 104 weeks, the RR for achieving a CMI in HAQ (> 0.22) was 1.4 (95% CI 1.3 to 1.6). The ATB was 24% (95% CI 16% to 31%) with a NNT of 5 (95% CI 3 to 7).At 24 weeks, the RR for preventing radiographic progression in patients receiving rituximab (two 1000 mg doses) in combination with methotrexate was 1.2 (95% CI 1.0 to 1.4) compared to methotrexate alone; 70% of patients receiving rituximab (two 1000 mg doses) in combination with methotrexate had no radiographic progression compared to 59% of controls. The ATB was 11% (95% CI 2% to 19%) and the NNT was 10 (95% CI 5 to 57). Similar benefits were observed at 52 to 56 weeks and 104 weeks.Statistically significantly more patients achieved a CMI on the physical and mental components of the quality of life, measured by the Short Form (SF)-36, in the rituximab (two 1000 mg doses) in combination with methotrexate-treated group compared with methotrexate alone at 24 to 52 weeks (RR 2.0, 95% CI 1.1 to 3.4; NNT 4, 95% CI 3 to 8 and RR 1.4, 95% CI 1.1 to 1.9; NNT 8, 95% CI 5 to 19, respectively); 34 and 13 more patients out of 100 showed an improvement in the physical component of the quality of life measure compared to methotrexate alone (95% CI 5% to 84%; 95% CI 7% to 8%, respectively).There was no evidence of a statistically significant difference in the rates of withdrawals because of adverse events or for other reasons (that is, withdrawal of consent, violation, administrative, failure to return) in either group. However, statistically significantly more people receiving the control drug withdrew from the study compared to those receiving rituximab (two 1000 mg doses) in combination with methotrexate at all times (RR 0.40, 95% CI 0.32 to 0.50; RR 0.61, 95% CI 0.40 to 0.91; RR 0.48, 95% CI 0.28 to 0.82; RR 0.58, 95% CI 0.45 to 0.75, respectively). At 104 weeks, 37% withdrew from the control group and 20% withdrew from the rituximab (two 1000 mg doses) in combination with methotrexate group. The absolute risk difference (ARD) was -20% (95% CI -34% to -5%) with a number needed to harm (NNH) of 7 (95% CI 5 to 11).A greater proportion of patients receiving rituximab (two 1000 mg doses) in combination with methotrexate developed adverse events after their first infusion compared to those receiving methotrexate monotherapy and placebo infusions (RR 1.6, 95% CI 1.3 to 1.9); 26% of those taking rituximab plus methotrexate reported more events associated with their first infusion compared to 16% of those on the control regimen with an ARD of 9% (95% CI 5% to 13%) and a NNH of 11 (95% CI 21 to 8). However, no statistically significant differences were noted in the rates of serious adverse events. AUTHORS' CONCLUSIONS Evidence from eight studies suggests that rituximab (two 1000 mg doses) in combination with methotrexate is significantly more efficacious than methotrexate alone for improving the symptoms of RA and preventing disease progression.
Collapse
Affiliation(s)
- Maria Angeles Lopez‐Olivo
- The University of Texas, M.D. Anderson Cancer CenterDepartment of General Internal Medicine1515 Holcombe BlvdUnit 1465HoustonTexasUSA77030
| | | | - Lynda McGahan
- L. McGahan Consulting33 Meadowlands Dr.OttawaONCanadaK2G 2R3
| | - Eduardo N Pollono
- University of South FloridaDepartment of Cardiovascular Sciences2 Tampa General Circle, 5rd FloorTampaFloridaUSA33606
| | - Maria E Suarez‐Almazor
- The University of Texas, M.D. Anderson Cancer CenterDepartment of General Internal Medicine1515 Holcombe BlvdUnit 1465HoustonTexasUSA77030
| | | |
Collapse
|
34
|
Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord 2014; 15:452. [PMID: 25539805 PMCID: PMC4391115 DOI: 10.1186/1471-2474-15-452] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 12/17/2014] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting approximately 1% of the UK adult population. Patients suffer considerable pain, stiffness and swelling and can sustain various degrees of joint destruction, deformity, and significant functional decline. In addition, the economic burden due to hospitalisation and loss of employment is considerable, with over 50% of patients being work-disabled within 10 years of diagnosis. Despite several biologic disease modifying anti-rheumatic drugs (bDMARD) now available, there is a lack of data to guide biologic sequencing. In the UK, second-line biologic treatment is restricted to a single option, rituximab. The aim of the SWITCH trial is to establish whether an alternative-mechanism-TNF-inhibitor (TNFi) or abatacept are as effective as rituximab in patients with RA who have failed an initial TNFi drug. METHODS/DESIGN SWITCH is a pragmatic, phase IV, multi-centre, parallel-group design, open-label, randomised, controlled trial (RCT) comparing alternative-mechanism-TNFi and abatacept with rituximab in patients with RA who have failed an initial TNFi drug. Participants are randomised in a 1:1:1 ratio to receive alternative mechanism TNFi, (monoclonal antibodies: infliximab, adalimumab, certolizumab or golimumab or the receptor fusion protein, etanercept), abatacept or rituximab during the interventional phase (from randomisation up to week 48). Participants are subsequently followed up to a maximum of 96 weeks, which constitutes the observational phase. The primary objective is to establish whether an alternative-mechanism-TNFi or abatacept are non-inferior to rituximab in terms of disease response at 24 weeks post randomisation. The secondary objectives include the comparison of alternative-mechanism-TNFi and abatacept to rituximab in terms of disease response, quality of life, toxicity, safety and structural and bone density outcomes over a 12-month period (48 weeks) and to evaluate the cost-effectiveness of switching patients to alternative active therapies compared to current practice. DISCUSSION SWITCH is a well-designed trial in this therapeutic area that aims to develop a rational treatment algorithm to potentially inform personalised treatment regimens (as opposed to switching all patients to only one available (and possibly unsuccessful) therapy), which may lead to long-term improved patient outcomes and gains in population health. TRIAL REGISTRATION UKCRN Portfolio ID: 12343; ISRCTN89222125 ; NCT01295151.
Collapse
Affiliation(s)
- Nuria C Navarro Coy
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, LS7 4SA, UK.
| | - Sarah Brown
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Ailsa Bosworth
- National Rheumatoid Arthritis Society (NRAS), Maidenhead, Berkshire, SL6 3RT, UK.
| | - Claire T Davies
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Paul Emery
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, LS7 4SA, UK.
| | - Colin C Everett
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Catherine Fernandez
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Janine C Gray
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Suzanne Hartley
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Claire Hulme
- Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9LJ, UK.
| | - Anne-Maree Keenan
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, LS7 4SA, UK.
| | | | - Anthony Redmond
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, LS7 4SA, UK.
| | - Catherine Reynolds
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - David Scott
- School of Medicine, University of East Anglia, Norfolk, NR4 7QN, UK.
| | - Linda D Sharples
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
| | - Sue Pavitt
- Centre for Health Sciences Research, Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9LJ, UK.
| | - Maya H Buch
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
- NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, LS7 4SA, UK.
| |
Collapse
|
35
|
Tokai N, Ogasawara M, Gorai M, Matsuki Y, Yamada Y, Murayama G, Sugisaki N, Nemoto T, Ando S, Minowa K, Kon T, Tada K, Matsushita M, Yamaji K, Tamura N, Makino S, Takasaki Y. Predictive value of bone destruction and duration of clinical remission for subclinical synovitis in rheumatoid arthritis patients. Mod Rheumatol 2014; 25:540-5. [DOI: 10.3109/14397595.2014.987421] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
36
|
Ogishima H, Tsuboi H, Umeda N, Horikoshi M, Kondo Y, Sugihara M, Suzuki T, Matsumoto I, Sumida T. Analysis of subclinical synovitis detected by ultrasonography and low-field magnetic resonance imaging in patients with rheumatoid arthritis. Mod Rheumatol 2014; 24:60-8. [PMID: 24261760 DOI: 10.3109/14397595.2013.854050] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
OBJECTIVE To assess the utilities of ultrasonography (US) and low-field magnetic resonance imaging (compacTscan, cMRI) in the diagnosis of subclinical synovitis of hand joints of patients with rheumatoid arthritis (RA). METHODS A total of 1,540 joints of 77 RA patients were examined clinically, using US, using cMRI, and the baseline X-ray examination was performed. Clinical synovitis was defined as joint tenderness or swelling. Subclinical synovitis was diagnosed by US and by cMRI. The incidence of bone erosion and joint space narrowing was assessed by X-ray examination performed at approximately 40 weeks of follow-up. RESULTS Of the hand joints examined, 294 (19.1 %) were diagnosed with clinical synovitis, and 218 joints (14.1 %) were diagnosed with subclinical synovitis. The remaining 1,028 joints (66.8 %) were synovitis-free on clinical examination and imaging. For the diagnosis of subclinical synovitis, cMRI (11.4 %) was significantly more sensitive than power Doppler signals detected by US (US-PD; 6.8 %) (P < 0.01), and the combination of US-PD and cMRI was more useful (14.1 %) than US-PD or cMRI alone (P < 0.05). Follow-up X-ray examination of 600 joints showed a significantly higher incidence of bone erosion in joints with subclinical synovitis than in synovitis-free joints (P < 0.05). CONCLUSION US-PD and cMRI are useful for detecting subclinical synovitis in patients with RA. Subclinical synovitis of the small joints of the hand can progress to bone destruction.
Collapse
Affiliation(s)
- Hiroshi Ogishima
- Department of Internal Medicine, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575 , Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ferraccioli G, Alivernini S, Gremese E. Biomarkers of joint damage in rheumatoid arthritis: where are we in 2013? J Rheumatol 2014; 40:1244-6. [PMID: 23908528 DOI: 10.3899/jrheum.130566] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
38
|
Kremer JM, Peterfy C, Russell AS, Emery P, Abud-Mendoza C, Sibilia J, Becker JC, Westhovens R, Genant HK. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol 2014; 41:1077-87. [PMID: 24786925 DOI: 10.3899/jrheum.130263] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
OBJECTIVE Evaluate the safety and efficacy of longterm abatacept (ABA) treatment over 5 years in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). METHODS Patients from the 1-year, double-blind Abatacept in Inadequate Responders to Methotrexate (AIM) study (NCT00048568) received open-label ABA (∼10 mg/kg) in the longterm extension (LTE). Safety was assessed for patients who received ≥ 1 ABA dose, and efficacy for patients randomized to ABA and treated in the LTE. Radiographs were evaluated for changes in Genant-modified Sharp scores. RESULTS Out of 652 patients, 539 entered the LTE (ABA, n = 378; placebo, n = 161). At Year 5, 72.4% were ongoing; discontinuation rates declined over time. Incidence rates of serious adverse events, serious infections, malignancies, and autoimmune events were 13.87, 2.84, 1.45, and 0.99 events/100 patient-years exposure, respectively. American College of Rheumatology 20 response was 82.3% (n = 373) and 83.6% (n = 268) at years 1 and 5, respectively. Disease Activity Score 28 C-reactive protein (DAS28-CRP) < 2.6 and ≤ 3.2 were achieved by 25.4% and 44.1% of patients at Year 1 (n = 370), and 33.7% and 54.7% at Year 5 (n = 267), respectively. Mean changes in DAS28-CRP and Health Assessment Questionnaire-Disability Index at Year 1 [-2.83 (n = 365) and -0.68 (n = 369)] were maintained at Year 5 [-3.14 (n = 264) and -0.77 (n = 271)] for patients continuing treatment. Of them, 59.5% (n = 291) and 45.1% (n = 235) remained free from radiographic progression at years 1 and 5, respectively. CONCLUSION In MTX-refractory patients with RA, longterm ABA treatment was well tolerated and provided consistent safety and sustained efficacy, with high patient retention. Radiographic progression continued to be inhibited with ongoing treatment.
Collapse
Affiliation(s)
- Joel M Kremer
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc.
| | - Charles Peterfy
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Anthony S Russell
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Paul Emery
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Carlos Abud-Mendoza
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Jean Sibilia
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Jean-Claude Becker
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Rene Westhovens
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| | - Harry K Genant
- From the Center for Rheumatology, Albany Medical College, Albany, New York; Spire Sciences Inc., Boca Raton, Florida, USA; Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada; Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK; Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí, San Luis Potosí, México; Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; Bristol-Myers Squibb, Princeton, New Jersey, USA; Department of Rheumatology, Universitaire Ziekenhuizenn Leuven, Leuven, Belgium; UCSF/Synarc, San Francisco, California, USA.Professional medical writing and editorial assistance funded by Bristol-Myers Squibb, Princeton, New Jersey, USA, and provided by Eve Guichard BSc (hons) of Caudex Medical, Oxford, UK.J.M. Kremer, MD, Center for Rheumatology, Albany Medical College; C. Peterfy, MD, PhD, FRCPC, Spire Sciences Inc.; A.S. Russell, FRCP, FRCPC, Division of Rheumatology, University of Alberta Hospital; P. Emery, MA, MD, FRCP, FRCPE, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust; C. Abud-Mendoza, MD, Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosí; J. Sibilia, MD, Service de Rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre; J-C. Becker, MD, Bristol-Myers Squibb*; R. Westhovens, MD, Department of Rheumatology, Universitaire Ziekenhuizenn Leuven; H.K. Genant, MD, UCSF/Synarc
| |
Collapse
|
39
|
Fukae J, Isobe M, Kitano A, Henmi M, Sakamoto F, Narita A, Ito T, Mitsuzaki A, Shimizu M, Tanimura K, Matsuhashi M, Kamishima T, Atsumi T, Koike T. Structural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity. Rheumatology (Oxford) 2014; 53:1608-12. [DOI: 10.1093/rheumatology/keu154] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Kaine JL. Abatacept for the treatment of rheumatoid arthritis: A review. Curr Ther Res Clin Exp 2014; 68:379-99. [PMID: 24692770 DOI: 10.1016/j.curtheres.2007.12.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/13/2007] [Indexed: 10/22/2022] Open
Abstract
BACKGROUND Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting synovial joints. Patients with persistent, active disease have traditionally been treated with disease-modifying antirheumatic drugs (DMARDs) (eg, methotrexate) or biologic agents (eg, tumor necrosis factor [TNF] antagonists). However, patients may discontinue these treatments due to toxicity, infection, or lack of efficacy. Two additional biologic therapies-rituximab and abatacept-are currently available for TNF-antagonist inadequate responders. Abatacept is also indicated for inadequate responders to traditional DMARDs. OBJECTIVES The aims of this review was to provide an overview of the issues surrounding the treatment of RA patients experiencing inadequate responses to current treatment and to discuss the current and future impact of abatacept on the RA treatment armamentarium. METHODS The MEDLINE, EMBASE, and BIOSIS databases were searched (search dates: January 1, 2000-September 19, 2007) using the terms abatacept or CTLA-4 or Orencia with rheumatoid arthritis. Full text articles in English were selected for relevance, and only articles presenting primary clinical trial data from randomized, placebo-controlled, clinical trials of abatacept were included. This review focused on the Phase III trials of abatacept in methotrexate and/or TNF-antagonist inadequate responders, as these trials had the largest number of patients and the longest study durations. RESULTS The literature search initially yielded 848 papers. A total of 12 articles fulfilled the inclusion criteria. Abatacept is a novel agent that has been reported to reduce the signs and symptoms of RA in patients with active RA with an inadequate response to DMARDs and/or TNF-antagonist treatment. In both of these patient populations, treatment with abatacept was found to provide clinically meaningful health-related quality-of-life benefits, such as improvements in physical function, activity limitation, sleep, and fatigue. Abatacept was reported to have a consistent safety and tolerability profile, with a low rate (3.5%-4.2%) of discontinuation due to adverse events. CONCLUSION The efficacy and tolerability data from Phase III clinical trials suggest that abatacept is an effective and generally well tolerated treatment option for RA patients with an inadequate response to methotrexate and/or TNF antagonists.
Collapse
|
41
|
Tobón G, Saraux A, Lukas C, Gandjbakhch F, Gottenberg JE, Mariette X, Combe B, Devauchelle-Pensec V. First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. Arthritis Care Res (Hoboken) 2014; 65:1907-15. [PMID: 23861163 DOI: 10.1002/acr.22078] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Accepted: 07/04/2013] [Indexed: 12/24/2022]
Abstract
OBJECTIVE A major goal in the treatment of recent arthritis is the prevention of joint destruction. The value of radiographic progression in the first year for predicting further radiographic progression has not been evaluated comparatively with conventional predictive factors. METHODS Patients with arthritis of <6 months' duration were included in the prospective French ESPOIR cohort. Radiographs were obtained and modified Sharp scores were determined by a blinded reader. The rate of progression was determined over the first year, then over the second and third years. Rapid progression was defined as a >5-point annual increase in the total Sharp score. RESULTS In total, 500 patients had complete data available after 3 years and were included. The total Sharp score indicated rapid progression in 123 patients (25%) in year 1 and 92 patients (18%) in years 2/3. By logistic regression, the variables independently associated with rapid progression in years 2/3 were year 1 rapid progression of the erosion and total Sharp scores, baseline erosion Sharp score, the serologic American College of Rheumatology/European League Against Rheumatism criterion, and interleukin-6 level. When these variables were combined, year 1 rapid progression made the largest contribution to predicting years 2/3 rapid progression. CONCLUSION First-year radiologic progression is the best independent predictor of further rapid progression in early arthritis.
Collapse
|
42
|
Chen DY, Yao L, Chen YM, Lin CC, Huang KC, Chen ST, Lan JL, Hsieh SLE. A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients. PLoS One 2014; 9:e86105. [PMID: 24465901 PMCID: PMC3897620 DOI: 10.1371/journal.pone.0086105] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Accepted: 12/06/2013] [Indexed: 12/14/2022] Open
Abstract
The pathogenic roles of myeloid DAP12-associating lectin-1(MDL-1) and DAP12 in human rheumatoid arthritis (RA) remain unknown. Frequencies of MDL-1-expressing monocytes in 22 active RA patients, 16 inactive RA patients, 12 osteoarthritis (OA) patients and 10 healthy controls (HC) were determined by flow-cytometry analysis. The mRNA expression levels of MDL-1 and DAP12 on PBMCs were evaluated by quantitative PCR, and their protein expression levels in the synovium were examined by immunohistochemistry. Significantly higher median percentages of circulating MDL-1-expressing monocytes were observed in active RA patients (53.6%) compared to inactive RA patients (34.1%), OA patients (27.9%), and HC (21.2%). Levels of MDL-1 and DAP12 gene expression in PBMCs and their protein expression in the synovium were significantly higher in active RA patients than in inactive RA or OA patients. MDL-1 levels were positively correlated with parameters of disease activity, articular damage, and levels of proinflammatory cytokines. MDL-1 activator (Dengue virus type 2 antigen) stimulation on PBMCs resulted in significantly enhanced levels of proinflammatory cytokines in RA patients compared to those in OA patients or HC, indicating that MDL-1 activation is functional. Frequencies of MDL-1-expressing monocytes and levels of MDL-1 and DAP12 gene expression significantly decreased after effective therapy. Concordant overexpression of MDL-1 and DAP12 were correlated with increased production of proinflammatory cytokines in RA patients, suggesting their roles in regulating articular inflammation.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing/genetics
- Adaptor Proteins, Signal Transducing/metabolism
- Arthritis, Rheumatoid/blood
- Arthritis, Rheumatoid/genetics
- Arthritis, Rheumatoid/metabolism
- Arthritis, Rheumatoid/pathology
- C-Reactive Protein/metabolism
- Cytokines/blood
- Female
- Flow Cytometry
- Gene Expression Regulation
- Humans
- Immunohistochemistry
- Inflammation/genetics
- Inflammation/metabolism
- Inflammation/pathology
- Inflammation Mediators/blood
- Joints/pathology
- Lectins, C-Type/genetics
- Lectins, C-Type/metabolism
- Leukocytes, Mononuclear/metabolism
- Male
- Membrane Proteins/genetics
- Membrane Proteins/metabolism
- Middle Aged
- Monocytes/metabolism
- Monocytes/pathology
- Osteoarthritis/genetics
- Osteoarthritis/metabolism
- Osteoarthritis/pathology
- Polymerase Chain Reaction
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/metabolism
- Synovial Membrane/metabolism
- Synovial Membrane/pathology
Collapse
Affiliation(s)
- Der-Yuan Chen
- Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
- Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan, R.O.C.
- Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
- Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.
| | - Ling Yao
- Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
| | - Yi-Ming Chen
- Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
- Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
| | - Chi-Chen Lin
- Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan, R.O.C.
| | - Kui-Chou Huang
- Department of Orthopedics and Traumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
| | - Szu-Ting Chen
- Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.
| | - Joung-Liang Lan
- Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
- Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Division of Immunology and Rheumatology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
- College of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C.
- * E-mail: (JLL); (SLEH)
| | - Shie-Liang Edmond Hsieh
- Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.
- Institute of Clinical Medicine, National Yang-Ming University, Taipei City, Taiwan
- * E-mail: (JLL); (SLEH)
| |
Collapse
|
43
|
Gandjbakhch F, Haavardsholm EA, Conaghan PG, Ejbjerg B, Foltz V, Brown AK, Døhn UM, Lassere M, Freeston JE, Olsen IC, Bøyesen P, Bird P, Fautrel B, Hetland ML, Emery P, Bourgeois P, Hørslev-Petersen K, Kvien TK, McQueen FM, Østergaard M. Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. J Rheumatol 2013; 41:398-406. [DOI: 10.3899/jrheum.131088] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Objective.To assess the predictive value of magnetic resonance imaging (MRI)-detected subclinical inflammation for subsequent radiographic progression in a longitudinal study of patients with rheumatoid arthritis (RA) in clinical remission or low disease activity (LDA), and to determine cutoffs for an MRI inflammatory activity acceptable state in RA in which radiographic progression rarely occurs.Methods.Patients with RA in clinical remission [28-joint Disease Activity Score-C-reactive protein (DAS28-CRP) < 2.6, n = 185] or LDA state (2.6 ≤ DAS28-CRP < 3.2, n = 69) with longitudinal MRI and radiographic data were included from 5 cohorts (4 international centers). MRI were assessed according to the Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS). Statistical analyses included an underlying conditional logistic regression model stratified per cohort, with radiographic progression as dependent variable.Results.A total of 254 patients were included in the multivariate analyses. At baseline, synovitis was observed in 95% and osteitis in 49% of patients. Radiographic progression was observed in 60 patients (24%). RAMRIS synovitis was the only independent predictive factor in multivariate analysis. ROC analysis identified a cutoff value for baseline RAMRIS synovitis score of 5 (maximum possible score 21). Rheumatoid factor (RF) status yielded a significant interaction with synovitis (p value = 0.044). RF-positive patients with a RAMRIS synovitis score of > 5 vs ≤ 5, had an OR of 4.4 (95% CI 1.72–11.4) for radiographic progression.Conclusion.High MRI synovitis score predicts radiographic progression in patients in clinical remission/LDA. A cutoff point for determining an MRI inflammatory activity acceptable state based on the RAMRIS synovitis score was established. Incorporating MRI in future remission criteria should be considered.
Collapse
|
44
|
Malleshi SN, V G M, Raina A, Patil K. A Subjective Assessment of Perceived Clarity of Indirect Digital Images and Processed Digital Images with Conventional Intra-oral Periapical Radiographs. J Clin Diagn Res 2013; 7:1793-6. [PMID: 24086916 DOI: 10.7860/jcdr/2013/5545.3278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2012] [Accepted: 06/03/2013] [Indexed: 01/23/2023]
Abstract
OBJECTIVES To compare and analyze the perceived clarity and diagnostic value of Conventional periapical Radiographs (CRs) with those of their Digitized Periapical Images (DIs) and Processed Digitized Periapical Images (PDIs) counterparts. MATERIAL AND METHODS Forty two intraoral periapical radiographs of patients with clinically suspected periapical pathosis were made to constitute the group of CRs. These were photographed by using a Canon Power Shot SD500 (7.1 Megapixel) digital camera and the unaltered images were transferred to a computer laptop, to form the group of DIs. Subsequently, the contrast and brightness of these images were modified to represent the group of PDIs. Two experienced oral radiologists independently evaluated 5 specific apical and periapical region parameters of all the 42 CRs, DIs and PDIs for perceived image quality and diagnostic value and graded them on a three point grading scale. Conventional radiographs served as the control. Data were analyzed by using paired t-test and Kappa analysis. RESULTS The clarity and diagnostic quality of the PDIs were statistically significant as compared to those of their conventional counterparts. In comparison, the DIs group fared badly, with deterioration of the image quality. The interobserver agreement was good and all the results were statistically significant. CONCLUSION Indirectly digitizing the radiographs by employing a digital camera and further digitally processing the images resulted in an improvement in their perceived clarity and they enhanced their diagnostic properties.
Collapse
Affiliation(s)
- Suchetha N Malleshi
- Lecturer, Department of Oral Medicine and Radiology, JSS Dental College and Hospital, JSS University , Mysore-15, Karnataka, India
| | | | | | | |
Collapse
|
45
|
Siebuhr AS, Bay-Jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal MA. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013; 15:R86. [PMID: 23945134 PMCID: PMC3978450 DOI: 10.1186/ar4266] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Accepted: 08/14/2013] [Indexed: 01/28/2023] Open
Abstract
Introduction Rheumatoid arthritis (RA) patients with structural progression are in most need of immediate treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-inflammatory treatment with tocilizumab (TCZ). Methods The LITHE-biomarker study (NCT00106535, n = 585) was a one-year phase III, double-blind, placebo (PBO)-controlled, parallel group study of TCZ 4 or 8 mg/kg every four weeks, in RA patients on stable doses of methotrexate (MTX). Spearman's ranked correlation was used to assess the correlation between baseline C1M levels and structural progression at baseline and at weeks 24 and 52. Multivariate regression was performed for delta structural progression. Change in C1M levels were studied as a function of time and treatment. Results At baseline, C1M was significantly correlated to C-reactive protein (P <0.0001), visual analog scale pain (P <0.0001), disease activity score28-erythrocyte sedimentation rate (DAS28-ESR) (P <0.0001), joint space narrowing (JSN) (P = 0.0056) and modified total Sharp score (mTSS) (P = 0.0006). Baseline C1M was significantly correlated with delta-JSN at Week 24 (R2 = 0.09, P = 0.0001) and at Week 52 (R2 = 0.27, P <0.0001), and with delta-mTSS at 24 weeks (R2 = 0.006, P = 0.0015) and strongly at 52 weeks (R2 = 0.013, P <0.0001) in the PBO group. C1M levels were dose-dependently reduced in the TCZ + MTX group. Conclusions Baseline C1M levels correlated with worsening joint structure over one year. Serum C1M levels may enable identification of those RA patients that are in most need of aggressive treatment Trial registration ClinicalTrials.gov: NCT00106535
Collapse
|
46
|
Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. J Rheumatol 2013; 40:579-89. [DOI: 10.3899/jrheum.120886] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Objective.To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA).Methods.Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response.Results.Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups.Conclusion.In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]
Collapse
|
47
|
Analysis of subclinical synovitis detected by ultrasonography and low-field magnetic resonance imaging in patients with rheumatoid arthritis. Mod Rheumatol 2013. [DOI: 10.1007/s10165-013-0849-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, McGonagle D. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. ACTA ACUST UNITED AC 2013; 63:603-8. [PMID: 21360489 DOI: 10.1002/art.30152] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Studies comparing 500 mg rituximab and 1,000 mg rituximab doses in rheumatoid arthritis have yielded conflicting data on clinical outcomes, but in all of these studies a subgroup of patients has had excellent responses at the lower dose. Historically, it was considered that rituximab uniformly depleted B cells at both doses. Using highly sensitive assays, we have shown that B cell depletion is variable and predictive of clinical response. Using the same techniques, we undertook the present study to test the hypothesis that the level of B cell depletion, rather than the rituximab dose, determines clinical response. METHODS Nineteen patients were treated with two 500-mg infusions of rituximab, and 61 patients were treated with two 1,000-mg infusions of rituximab. Highly sensitive flow cytometry was performed at 0, 2, 6, 14, and 26 weeks. European League Against Rheumatism (EULAR) response rates at 6 months were compared between patients with and those without complete depletion at each dose. RESULTS The median B cell count was numerically higher at all time points following therapy in the 500 mg rituximab group. Twenty-five percent of patients in the 500 mg rituximab group had complete depletion at 2 weeks, compared with 49% of those in the 1,000 mg rituximab group. Complete depletion at 2 weeks after treatment with 500 mg rituximab was associated with lower baseline preplasma cell counts (P = 0.047). Most patients responded after either dose, but response was related to B cell depletion. Notably, in the 500 mg rituximab group all patients with complete depletion had a EULAR good response (P = 0.011). CONCLUSION This pilot study suggests that the degree of B cell depletion, rather than the dose of rituximab, determines clinical response. It may be possible to predict which patients will respond to lower-dose rituximab, and this may allow more cost-effective treatment.
Collapse
Affiliation(s)
- Edward M Vital
- National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, UK
| | | | | | | | | | | | | |
Collapse
|
49
|
FLEISCHMANN ROYM, HALLAND ANNEMARIE, BRZOSKO MAREK, BURGOS-VARGAS RUBEN, MELA CHRISTOPHER, VERNON EMMA, KREMER JOELM. Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. J Rheumatol 2013; 40:113-26. [DOI: 10.3899/jrheum.120447] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Objective.To assess radiographic progression, physical function, clinical disease activity, and safety in patients with rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX) and who were treated with tocilizumab-MTX or MTX during Year 2 of a 2-year study.Methods.During Year 1, patients were randomized to placebo-MTX, 4 mg/kg tocilizumab-MTX, or 8 mg/kg tocilizumab-MTX. During Year 2, patients continued the initial double-blind treatment or switched to open-label 8 mg/kg tocilizumab-MTX. Co-primary endpoints at Week 104 were mean change from baseline in Genant-modified Total Sharp Score (GmTSS) and adjusted mean area under the curve (AUC) for change from baseline in the Health Assessment Questionnaire–Disability Index (HAQ-DI). Signs and symptoms of RA and safety were also evaluated.Results.At Week 104, mean change from baseline in GmTSS was significantly lower for patients initially randomized to tocilizumab-MTX 4 mg/kg (0.58; p = 0.0025) or 8 mg/kg (0.37; p < 0.0001) than for patients initially randomized to placebo-MTX (1.96). Adjusted mean AUC of change from baseline in HAQ-DI was also significantly lower in patients initially randomized to tocilizumab-MTX 4 mg/kg (–287.5; p < 0.0001) or 8 mg/kg (–320.8; p < 0.0001) than in patients initially randomized to placebo-MTX (–139.4). Signs and symptoms of RA were maintained or showed improvement. No new safety signals were noted.Conclusion.Compared with placebo-MTX, tocilizumab-MTX significantly inhibited structural joint damage and improved physical function in patients with RA who previously had inadequate response to MTX. An extension of this study is continuing and will provide additional longterm efficacy and safety data. National Clinical Trials registry NCT00106535.
Collapse
|
50
|
Fukae J, Isobe M, Kitano A, Henmi M, Sakamoto F, Narita A, Ito T, Mitsuzaki A, Shimizu M, Tanimura K, Matsuhashi M, Kamishima T, Atsumi T, Koike T. Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint. Rheumatology (Oxford) 2012. [PMID: 23192908 DOI: 10.1093/rheumatology/kes310] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Jun Fukae
- Hokkaido Medical Center for Rheumatic Diseases, 1-45, 3-Chome, 1-Jo, Kotoni, Nishi-ku, Sapporo 063-0811, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|